CertaraCERT +0.83%59 Days Payable is 7.80 as of Mar. 2026, which is 62% below its 10-year median of 20.57. GuruFocus rates CERT with a GF Score™ of 59/100 and a GF Value™ of $13.40 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 608 Healthcare Providers & Services companies, Certara ranks worse than 93.42% on this metric.
Certara's average Accounts Payable for the
three
months ended in Mar. 2026 was $3.6 Mil. Certara's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $41.6 Mil.
Hence, Certara's Days Payable for the
three
months ended in Mar. 2026 was 7.80.
The historical rank and industry rank for Certara's Days Payable or its related term are showing as below:
CERT'
s Days Payable Range Over the Past 10 Years
Min: 7.85 Med: 20.57 Max: 25.22
Current: 9.56
During the past 8 years, Certara's highest Days Payable was 25.22. The lowest was 7.85. And the median was 20.57.
CERT's Days Payable is ranked worse than 93.42% of 608
companies
in the Healthcare Providers & Services industry
Industry Median: 58.08
vs CERT: 9.56
Certara's Days Payable
declined
from Mar. 2025 (9.42) to Mar. 2026 (7.80).
It may suggest that Certaraaccelerated paying its suppliers.
Certara Days Payable Related Terms
Certara Days Payable Historical Data
* Premium members only.
The historical data trend for Certara's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Certara's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Certara Days Payable vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Certara's Days Payable distribution charts can be found below:
* The bar in red indicates where Certara's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Certara's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Certara (CERT) has a Days Payable of 7.80 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Certara and its competitors. This is 62% below median its historical median of 20.57. Over the past decade, Certara's Days Payable has ranged from 7.85 to 25.22. According to the industry distribution chart, Certara ranks #568 out of 608 companies in the Healthcare Providers & Services industry, placing it in the top 93.4%.
Is Certara's Days Payable too high?
Certara's current Days Payable of 7.80 is 62% below median its 10-year median of 20.57. Over the past 10 years, this metric has ranged from a low of 7.85 to a high of 25.22. The Healthcare Providers & Services industry median Days Payable is 58.08. Certara's value of 7.80 is 86.6% below this industry median. Based on the distribution chart, Certara ranks #568 out of 608 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Certara has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Certara's Days Payable compare to TALK and GDRX?
According to the Healthcare Providers & Services industry distribution chart, Certara ranks #568 out of 608 companies for Days Payable. This places Certara in the lower half of its industry. The industry median Days Payable is 58.08. Certara's value of 7.80 is 86.6% below this benchmark. Historically, Certara's own Days Payable has ranged from 7.85 to 25.22 over the past decade. While the company's 10-year median is 20.57 vs. the industry median of 58.08, Certara has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Healthcare Providers & Services company?
The median Days Payable among Healthcare Providers & Services companies is 58.08, based on 608 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Certara's current Days Payable of 7.80 is 86.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Certara and its competitors. For the Healthcare Providers & Services industry, the median Days Payable is 58.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Certara's current Days Payable is 7.80, which is 62% below median its own 10-year median of 20.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Certara stock overvalued right now?
Based on GuruFocus' analysis, Certara (CERT) is currently considered Possible Value Trap. The stock's GF Value™ is $13.40, compared to a current price of $5.45 — trading 59.4% below its estimated fair value. The current Days Payable is 7.80, which is 62% below median its 10-year median of 20.57 and 86.6% below the Healthcare Providers & Services industry median of 58.08. Certara's overall GF Score™ is 59/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Certara (CERT), the current Days Payable is 7.80 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Certara (CERT) Overvalued in 2026?
Based on GuruFocus' analysis, Certara stock appears to be undervalued.
The current stock price of $5.45 is trading 59.4% below its estimated GF Value™ of $13.40.
GuruFocus considers Certara to be Possible Value Trap.
Key valuation signals for CERT:
Days Payable: 7.80 (62% below median its 10-year median of 20.57)
GF Value™: $13.40 vs. price of $5.45 (59.4% below fair value)
Industry Position: 86.6% below the Healthcare Providers & Services median (#568 of 608)
No single metric tells the full story. See the CERT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.
59GF Score
Get the complete analysis for CERT
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CERT has been successfully added to your 
